×
About 7,388 results

ALLMedicine™ Splenomegaly Center

Research & Reviews  2,354 results

Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
https://doi.org/10.1080/14656566.2023.2192350
Expert Opinion on Pharmacotherapy; Tremblay D, Mascarenhas J

Mar 17th, 2023 - Myelofibrosis is a hematologic malignancy with a variety of clinical manifestations including splenomegaly, which is present in approximately 80% of newly diagnosed patients. JAK inhibitors are the mainstay of pharmacologic treatment for splenomeg...

Immune Thrombocytopenia (ITP)
http://emedicine.medscape.com/article/202158-overview

Mar 13th, 2023 - Practice Essentials Immune thrombocytopenia (ITP) is a syndrome in which platelets become coated with autoantibodies to platelet membrane antigens, resulting in splenic sequestration and phagocytosis by mononuclear macrophages. The resulting short...

Immune Thrombocytopenia (ITP)
https://emedicine.medscape.com/article/202158-overview

Mar 13th, 2023 - Practice Essentials Immune thrombocytopenia (ITP) is a syndrome in which platelets become coated with autoantibodies to platelet membrane antigens, resulting in splenic sequestration and phagocytosis by mononuclear macrophages. The resulting short...

Immune Thrombocytopenia (ITP)
https://emedicine.medscape.com/article/202158-print

Mar 13th, 2023 - Practice Essentials Immune thrombocytopenia (ITP) is a syndrome in which platelets become coated with autoantibodies to platelet membrane antigens, resulting in splenic sequestration and phagocytosis by mononuclear macrophages. The resulting short...

Ruxolitinib in Patients With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT05762874

Mar 10th, 2023 - Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell in which the abnormal stem cell population releases several cytokines and growth factors into the bone marrow microenvironment, it is pathologically characterized b...

see more →

Guidelines  1 results

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953894
Blood Oliveira JB, Bleesing JJ et. al.

Jun 12th, 2010 - Lymphadenopathy in children for which no infectious or malignant cause can be ascertained constitutes a challenging diagnostic dilemma. Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  104 results

Ruxolitinib in Patients With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT05762874

Mar 10th, 2023 - Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell in which the abnormal stem cell population releases several cytokines and growth factors into the bone marrow microenvironment, it is pathologically characterized b...

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Mar 9th, 2023 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Mar 8th, 2023 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)
https://clinicaltrials.gov/ct2/show/NCT02298647

Feb 13th, 2023 - Gangliosidosis: Gangliosides are complex compunds consisting of a glycosphingolipid and a sialic acid and are located at the cell surface where they are responsible for detecting extracellular molecules. Gangliosides are mainly located in the nerv...

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04322383

Jan 25th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases per year in the US. BRAF V600E mutation is very common in classic HCL. HCL variant (HCLv) is wild type for BRAF an...

see more →

News  468 results

JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/othercancers/102883

Jan 30th, 2023 - Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and interme...

Kikuchi-Fujimoto Disease: A Case Report of Fever and Lymphadenopathy in a Young White Man
https://www.mdedge.com/fedprac/article/260596/mixed-topics/kikuchi-fujimoto-disease-case-report-fever-and-lymphadenopathy
David Kellner, MD, Tijana Temelkovsk et. al.

Jan 16th, 2023 - Kikuchi-Fujimoto disease (KFD) is a rare, usually self-limited cause of cervical lymphadenitis that is more prevalent among patients of Asian descent. 1 The pathogenesis of KFD remains unknown.

Treatments for MCL Continue to Progress
https://www.onclive.com/view/treatments-for-mcl-continue-to-progress

Nov 18th, 2022 - As research and treatment options for patients with mantle cell lymphoma (MCL) continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step...

Dr. Goy on the Clinical Implications of Treating Indolent MCL
https://www.onclive.com/view/dr-goy-on-the-clinical-implications-of-treating-indolent-mcl

Nov 15th, 2022 - Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, discusses the cl...

Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS
https://www.onclive.com/view/novel-combinations-could-spark-shift-in-treatment-paradigm-for-higher-risk-mds

Sep 27th, 2022 - Several clinical trials are exploring combination therapies that include agents such as venetoclax (Venclexta), magrolimab, sabatolimab (MBG453), and others, with the goal of improving upon the efficacy achieved with hypomethylating agents in pati...

see more →

Patient Education  14 results see all →